12/ Viral RNA Targeting: Novel approaches such as CRISPR-based treatments could potentially deactivate persistent viral RNA, but further validation is needed.
Comments
Log in with your Bluesky account to leave a comment
13/ Combination Trials: Combining therapeutics - such as antivirals together with mAbs or immune system therapies - may be needed to most effectively target viral reservoirs.
14/ "Our approach recognizes the importance of a multifactorial strategy," says report senior author Michael Peluso MD, an infectious disease researcher at the University of California, San Francisco (UCSF) School of Medicine.
15/ "We believe that combining therapies targeting both the virus and the immune system may be the best way forward, especially if dealing with persistent viral reservoirs in immune-protected tissues."
16/ The report also highlights the urgent need to develop validated biomarkers capable of detecting persistent virus in accessible fluids like blood and saliva—an effort with immense potential to accelerate clinical trials, but one that remains underdeveloped.
17/ "Advancing such tests represents a major opportunity for the biotech sector," says report first author Amy Proal PhD, who serves as President of the PolyBio Research Foundation.
18/ “We know what long COVID clinical trials to run - and we have a plan to do it," says Peluso. “Now we need everyone on board to collaborate and expand funding and industry support to make it happen. The health of millions is at stake.”
Comments